29 results on '"Kristensen, Gunnar B"'
Search Results
2. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
- Author
-
Lindemann, Kristina, Kildal, Wanja, Kleppe, Andreas, Tobin, Kari Anne R., Pradhan, Manohar, Isaksen, Maria X., Vlatkovic, Ljiljana, Danielsen, Håvard E., Kristensen, Gunnar B., and Askautrud, Hanne A.
- Published
- 2024
- Full Text
- View/download PDF
3. Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience
- Author
-
Sert, Bilal M., Kristensen, Gunnar B., Kleppe, Andreas, and Dørum, Anne
- Published
- 2021
- Full Text
- View/download PDF
4. DCE-MRI–Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma
- Author
-
Simonsen, Trude G., Lund, Kjersti V., Hompland, Tord, Kristensen, Gunnar B., and Rofstad, Einar K.
- Published
- 2018
- Full Text
- View/download PDF
5. DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
- Author
-
Lund, Kjersti V., Simonsen, Trude G., Kristensen, Gunnar B., and Rofstad, Einar K.
- Published
- 2020
- Full Text
- View/download PDF
6. Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials
- Author
-
Vergote, Ignace, Coens, Corneel, Nankivell, Matthew, Kristensen, Gunnar B., Parmar, Mahesh K. B., Ehlen, Tom, Jayson, Gordon C., Johnson, Nick, Swart, Ann Marie, Verheijen, René, McCluggage, W. Glenn, Perren, Tim, Panici, Pierluigi Benedetti, Kenter, Gemma, Casado, Antonio, Mendiola, Cesar, Stuart, Gavin, Reed, Nick S., and Kehoe, Sean
- Published
- 2019
- Full Text
- View/download PDF
7. Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
- Author
-
Hompland, Tord, Lund, Kjersti V., Ellingsen, Christine, Kristensen, Gunnar B., and Rofstad, Einar K.
- Published
- 2014
- Full Text
- View/download PDF
8. A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
- Author
-
Vistad, Ingvild, Bjørge, Line, Solheim, Olesya, Fiane, Bent, Sachse, Kurt, Tjugum, Jostein, Skrøppa, Siri, Bentzen, Anne G., Stokstad, Trine, Iversen, Grete A., Salvesen, Helga B., Kristensen, Gunnar B., and Dørum, Anne
- Published
- 2017
- Full Text
- View/download PDF
9. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data.
- Author
-
Karamouza, Eleni, Glasspool, Rosalind M., Kelly, Caroline, Lewsley, Liz-Anne, Carty, Karen, Kristensen, Gunnar B., Ethier, Josee-Lyne, Kagimura, Tatsuo, Yanaihara, Nozomu, Cecere, Sabrina Chiara, You, Benoit, Boere, Ingrid A., Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Proust-Lima, Cécile, and Paoletti, Xavier
- Subjects
THERAPEUTIC use of antineoplastic agents ,OVARIAN tumors ,PREDICTIVE tests ,META-analysis ,CONFIDENCE intervals ,SYSTEMATIC reviews ,CANCER chemotherapy ,EARLY detection of cancer ,COMPARATIVE studies ,RESEARCH funding ,TUMOR antigens ,TUMOR markers ,PREDICTION models ,RECEIVER operating characteristic curves ,WOMEN'S health ,OVERALL survival - Abstract
Simple Summary: Cancer antigen 125 (CA-125) is a protein found at a high concentration in the blood of patients with specific types of cancer, mainly ovarian cancer. In 2004, the Gynecologic Cancer Intergroup (GCIG) proposed criteria defining response to treatment, as well as disease progression, based on the CA-125 concentration. Ever since, for the follow-up of ovarian cancer patients, the CA-125 concentration and/or CT-scans are used. This paper aims to compare different summaries of CA-125 evolution in the 3 to 6 months following treatment initiation in newly diagnosed advanced ovarian cancer and explore their prognostic capacity to predict overall survival. Based on individual patient data from the GCIG meta-analysis, we propose the most appropriate timeframe between follow-up and the prediction horizon in order to obtain robust, dynamic, individual predictions. (1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients' monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged individual patient data from the Gynecologic Cancer Intergroup (GCIG) meta-analysis (N = 5573) to compare different approaches summarizing the early trajectory of CA-125 before the prediction time (called the landmark time) at 3 or 6 months after treatment initiation in order to predict overall survival. These summaries included observed and estimated measures obtained by a linear mixed model (LMM). Their performances were evaluated by 10-fold cross-validation with the Brier score and the area under the ROC (AUC). (3) Results: The estimated value and the last observed value at 3 months were the best measures used to predict overall survival, with an AUC of 0.75 CI 95% [0.70; 0.80] at 24 and 36 months and 0.74 [0.69; 0.80] and 0.75 [0.69; 0.80] at 48 months, respectively, considering that CA-125 over 6 months did not improve the AUC, with 0.74 [0.68; 0.78] at 24 months and 0.71 [0.65; 0.76] at 36 and 48 months. (4) Conclusions: A 3-month surveillance provided reliable individual information on overall survival until 48 months for patients receiving first-line chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer.
- Author
-
Nilsen, Anja, Hillestad, Tiril, Skingen, Vilde E., Aarnes, Eva-Katrine, Fjeldbo, Christina S., Hompland, Tord, Sandø Evensen, Tina, Stokke, Trond, Kristensen, Gunnar B., Grallert, Beata, and Lyng, Heidi
- Published
- 2022
- Full Text
- View/download PDF
11. Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model.
- Author
-
Lund, Kjersti V., Simonsen, Trude G., Kristensen, Gunnar B., and Rofstad, Einar K.
- Subjects
BIOMARKERS ,BIOLOGICAL models ,CANCER relapse ,CISPLATIN ,DIAGNOSTIC imaging ,MAGNETIC resonance imaging ,COMPUTERS in medicine ,MULTIVARIATE analysis ,RISK assessment ,SURVIVAL ,CERVIX uteri tumors ,TREATMENT effectiveness ,RECEIVER operating characteristic curves ,DESCRIPTIVE statistics ,CHEMORADIOTHERAPY - Abstract
Background: There is significant evidence that DCE-MRI may have the potential to provide clinically useful biomarkers of the outcome of locally advanced cervical carcinoma. However, there is no consensus on how to analyze DCE-MRI data to arrive at the most powerful biomarkers. The purpose of this study was to analyze DCE-MRI data of cervical cancer patients by using the Brix pharmacokinetic model and to compare the biomarkers derived from the Brix analysis with biomarkers determined by non-model-based analysis [i.e., low-enhancing tumor volume (LETV) and tumor volume with increasing signal (TVIS)] of the same patient cohort. Material and methods: DCE-MRI recordings of 80 patients (FIGO stage IB–IVA) treated with concurrent cisplatin-based chemoradiotherapy were analyzed voxel-by-voxel, and frequency distributions of the three parameters of the Brix model (A
Brix , kep , and kel ) were determined. Moreover, risk volumes were calculated from the Brix parameters and termed RV-ABrix , RV-kep , and RV-kel , where the RVs represent the tumor volume with voxel values below a threshold value determined by ROC analysis. Disease-free survival (DFS) and overall survival (OS) were used as measures of treatment outcome. Results: Significant associations between the median value or any other percentile value of ABrix , kep , or kel and treatment outcome were not found. However, RV-ABrix , RV-kep , and RV-kel correlated with DFS and OS. Multivariate analysis revealed that the prognostic power of RV-ABrix , RV-kep , and RV-kel was independent of well-established clinical prognostic factors. RV-ABrix , RV-kep , and RV-kel correlated with each other as well as with LETV and TVIS. Conclusion: Strong biomarkers of the outcome of locally advanced cervical carcinoma can be provided by subjecting DCE-MRI series to pharmacokinetic analysis using the Brix model. The prognostic power of these biomarkers is not necessarily superior to that of biomarkers identified by non-model-based analyses. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
12. Egenskaper ved kreftcellenes DNA påvirker prognosen.
- Author
-
KILDAL, WANJA, PRADHAN, MANOHAR, CYLL, KAROLINA, JACOBSEN, JØRN E., KRISTENSEN, GUNNAR B., and DANIELSEN, HÅVARD E.
- Published
- 2017
13. Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer.
- Author
-
Lund, Kjersti V., Simonsen, Trude G., Kristensen, Gunnar B., and Rofstad, Einar K.
- Subjects
CERVIX uteri tumors ,MAGNETIC resonance imaging ,MULTIVARIATE analysis ,SURVIVAL analysis (Biometry) ,TREATMENT effectiveness ,CHEMORADIOTHERAPY ,PROGNOSIS - Abstract
Background:Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may provide prognostic biomarkers for cervix carcinoma. We have shown previously that the early phase of the signal intensity-versus-time curve (SITC) may have significant prognostic power. The purpose of the present investigation was to explore the prognostic value of the late phase of the SITC. Material and methods:DCE-MRI data of 80 patients (FIGO stage IB–IVA) treated with concurrent chemoradiotherapy were examined. Four parameters were calculated from the late-phase SITC: tumor volume with decreasing signal, tumor fraction with decreasing signal, tumor volume with increasing signal (TVIS), and tumor fraction with increasing signal. Results:Multivariate analysis involving clinical parameters and late-phase SITC parameters suggested that TVIS is a strong independent prognostic factor for both disease-free and overall survival. When early-phase SITC parameters were included in the multivariate analysis, the early-phase SITC, but not the late-phase SITC, was found to have independent prognostic value. Conclusion:The late-phase SITC can provide prognostic factors for the outcome of cervix carcinoma, that is, a large tumor volume with increasing late-phase SITCs is associated with poor outcome. However, the prognostic power of the late-phase SITC is not as strong as that of the early-phase SITC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.
- Author
-
Zhou, Cong, Clamp, Andrew, Backen, Alison, Berzuini, Carlo, Renehan, Andrew, Banks, Rosamonde E, Kaplan, Richard, Scherer, Stefan J, Kristensen, Gunnar B, Pujade-Lauraine, Eric, Dive, Caroline, and Jayson, Gordon C
- Abstract
Background: There is a critical need for predictive/resistance biomarkers for VEGF inhibitors to optimise their use.Methods: Blood samples were collected during and following treatment and, where appropriate, upon progression from ovarian cancer patients in ICON7, a randomised phase III trial of carboplatin and paclitaxel with or without bevacizumab. Plasma concentrations of 15 circulating angio-biomarkers were measured using a validated multiplex ELISA, analysed through a novel network analysis and their relevance to the PFS then determined.Results: Samples (n=650) were analysed from 92 patients. Bevacizumab induced correlative relationships between Ang1 and Tie2 plasma concentrations, which reduced after initiation of treatment and remained decreased until progressive disease occurred. A 50% increase from the nadir in the concentration of circulating Tie2 (or the product of circulating Ang1 and Tie2) predicted tumour progression. Combining Tie2 with GCIG-defined Ca125 data yielded a significant improvement in the prediction of progressive disease in patients receiving bevacizumab in comparison with Ca125 alone (74.1% vs 47.3%, P<1 × 10(-9)).Conclusions: Tie2 is a vascular progression marker for bevacizumab-treated ovarian cancer patients. Tie2 in combination with Ca125 provides superior information to clinicians on progressive disease in patients with VEGFi-treated ovarian cancers. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
15. Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients.
- Author
-
Fjeldbo, Christina S., Aarnes, Eva-Katrine, Malinen, Eirik, Kristensen, Gunnar B., and Lyng, Heidi
- Subjects
CERVICAL cancer diagnosis ,CERVICAL cancer ,SQUAMOUS cell carcinoma ,GENE expression ,BIOMARKERS ,REVERSE transcriptase polymerase chain reaction ,HYPOXEMIA ,GENETICS - Abstract
Hypoxia is an adverse factor in cervical cancer, and hypoxia-related gene expression could be a powerful biomarker for identifying the aggressive hypoxic tumors. Reverse transcription quantitative PCR (RT-qPCR) is a valuable method for gene expression studies, but suitable reference genes for data normalization that are independent of hypoxia status and clinical parameters of cervical tumors are lacking. In the present work, we aimed to identify reference genes for RT-qPCR studies of hypoxia in squamous cervical cancer. From 422 candidate reference genes selected from the literature, we used Illumina array-based expression profiles to identify 182 genes not affected by hypoxia in cervical cancer, i.e. genes regulated by hypoxia in eight cervical cancer cell lines or correlating with the hypoxia-associated dynamic contrast-enhanced magnetic resonance imaging parameter A
Brix in 42 patients, were excluded. Among the 182 genes, nine candidates (CHCHD1, GNB2L1, IPO8, LASP1, RPL27A, RPS12, SOD1, SRSF9, TMBIM6) that were not associated with tumor volume, stage, lymph node involvement or disease progression in array data of 150 patients, were selected for further testing by RT-qPCR. geNorm and NormFinder analyses of RT-qPCR data of 74 patients identified CHCHD1, SRSF9 and TMBIM6 as the optimal set of reference genes, with stable expression both overall and across patient subgroups with different hypoxia status (ABrix ) and clinical parameters. The suitability of the three reference genes were validated in studies of the hypoxia-induced genes DDIT3, ERO1A, and STC2. After normalization, the RT-qPCR data of these genes showed a significant correlation with Illumina expression (P<0.001, n = 74) and ABrix (P<0.05, n = 32), and the STC2 data were associated with clinical outcome, in accordance with the Illumina data. Thus, CHCHD1, SRSF9 and TMBIM6 seem to be suitable reference genes for studying hypoxia-related gene expression in squamous cervical cancer samples by RT-qPCR. Moreover, STC2 is a promising prognostic hypoxia biomarker in cervical cancer. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
16. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.
- Author
-
Lando, Malin, Fjeldbo, Christina S, Wilting, Saskia M, C Snoek, Barbara, Aarnes, Eva-Katrine, Forsberg, Malin F, Kristensen, Gunnar B, Steenbergen, Renske DM, and Lyng, Heidi
- Published
- 2015
- Full Text
- View/download PDF
17. Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas.
- Author
-
Nielsen, Birgitte, Hveem, Tarjei Sveinsgjerd, Kildal, Wanja, Abeler, Vera M., Kristensen, Gunnar B., Albregtsen, Fritz, Danielsen, Håvard E., and Rohde, Gustavo K.
- Abstract
Nuclear texture analysis measures the spatial arrangement of the pixel gray levels in a digitized microscopic nuclear image and is a promising quantitative tool for prognosis of cancer. The aim of this study was to evaluate the prognostic value of entropy-based adaptive nuclear texture features in a total population of 354 uterine sarcomas. Isolated nuclei (monolayers) were prepared from 50 µm tissue sections and stained with Feulgen-Schiff. Local gray level entropy was measured within small windows of each nuclear image and stored in gray level entropy matrices, and two superior adaptive texture features were calculated from each matrix. The 5-year crude survival was significantly higher ( P < 0.001) for patients with high texture feature values (72%) than for patients with low feature values (36%). When combining DNA ploidy classification (diploid/nondiploid) and texture (high/low feature value), the patients could be stratified into three risk groups with 5-year crude survival of 77, 57, and 34% (Hazard Ratios (HR) of 1, 2.3, and 4.1, P < 0.001). Entropy-based adaptive nuclear texture was an independent prognostic marker for crude survival in multivariate analysis including relevant clinicopathological features (HR = 2.1, P = 0.001), and should therefore be considered as a potential prognostic marker in uterine sarcomas. © The Authors. Published 2014 International Society for Advancement of Cytometry [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification.
- Author
-
Kasius, Jenneke C., Pijnenborg, Johanna M. A., Lindemann, Kristina, Forsse, David, van Zwol, Judith, Kristensen, Gunnar B., Krakstad, Camilla, Werner, Henrica M. J., and Amant, Frédéric
- Subjects
LYMPH node surgery ,BIOPSY ,METASTASIS ,CANCER relapse ,RISK assessment ,CANCER patients ,TUMOR classification ,PERITONEUM ,ENDOMETRIAL tumors ,TUMOR markers ,CYTOLOGY - Abstract
Simple Summary: Endometrial cancer (EC) is the most common gynaecologic malignancy in developed countries. Most patients are sufficiently treated with removal of uterus, tubes and ovaries. It depends on the estimated risk of metastases at diagnosis if more extensive surgery (removal of lymph nodes, peritoneum and/or omentum), to detect small metastases, is indicated. Metastases are associated with a higher risk of recurrence and justify adjuvant treatment (i.e., radiotherapy and/or chemotherapy). Recently it is advised to also subdivide EC into four molecular subgroups. Each subgroup is highly associated to a certain risk of recurrence and helps to decide for adjuvant treatment. What surgery should be performed in each of the subgroups is currently unknown. Moreover, it is uncertain if integration of other factors into the molecular classification could help to improve the risk classification. This review summarizes different aspects of surgery. Moreover, the relation between metastases and other factors including molecular classification are evaluated. Endometrial cancer (EC) is the most common gynaecologic malignancy in developed countries. The main challenge in EC management is to correctly estimate the risk of metastases at diagnosis and the risk to develop recurrences in the future. Risk stratification determines the need for surgical staging and adjuvant treatment. Detection of occult, microscopic metastases upstages patients, provides important prognostic information and guides adjuvant treatment. The molecular classification subdivides EC into four prognostic subgroups: POLE ultramutated; mismatch repair deficient (MMRd); nonspecific molecular profile (NSMP); and TP53 mutated (p53abn). How surgical staging should be adjusted based on preoperative molecular profiling is currently unknown. Moreover, little is known whether and how other known prognostic biomarkers affect prognosis prediction independent of or in addition to these molecular subgroups. This review summarizes the factors incorporated in surgical staging (i.e., peritoneal washing, lymph node dissection, omentectomy and peritoneal biopsies), and its impact on prognosis and adjuvant treatment decisions in an era of molecular classification of EC. Moreover, the relation between FIGO stage and molecular classification is evaluated including the current gaps in knowledge and future perspectives. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer.
- Author
-
Lindemann, Kristina, Smogeli, Elisabeth, Småstuen, Milada Cvancarova, Bruheim, Kjersti, Trovik, Jone, Nordberg, Terje, Kristensen, Gunnar B., Werner, Henrica M. J., Nakken, Esten, and Katsaròs, Dionyssios
- Subjects
RESEARCH ,CONFIDENCE intervals ,CANCER relapse ,MEDICAL cooperation ,RETROSPECTIVE studies ,TREATMENT effectiveness ,ENDOMETRIAL tumors ,KAPLAN-Meier estimator ,DESCRIPTIVE statistics ,SALVAGE therapy ,PROPORTIONAL hazards models - Abstract
Simple Summary: This multicenter retrospective study aimed to describe the outcomes of patients with endometrial cancer after central pelvic/vaginal relapse treated with radical radiotherapy (RT). We included 139 patients with a median follow-up time of 6.66 years. Patients were treated with external beam radiotherapy to elective pelvic lymph-node regions and boost to the pelvic tumor. During follow-up, 55 (39.6%) patients developed a second relapse, the majority (75%) with disease sites outside the radiation field. Risk group at primary diagnosis and type of boost administration were independent predictors of progression-free and overall survival. Five-year overall survival for the whole cohort was 68% (95% CI: 59–75%). The majority of isolated pelvic recurrences in RT-naive women with EC can be successfully salvaged by RT but survival in high-risk patients remains suboptimal. Individualizing of adjuvant treatment in first line and better treatment alternatives at relapse are important to ultimately improve survival. (1) Background: This study evaluated the clinical outcome after salvage radiotherapy for first pelvic relapse after endometrial cancer (EC). (2) Methods: This multicenter retrospective study included EC patients with first central pelvic relapse without lymph node involvement treated with curative intent. Progression-free (PFS) and overall survival (OS) were calculated with the Kaplan–Meier method and possible predictive factors for risk of relapse and mortality were identified using the Cox model. (3) Results: We included 139 patients with median EQD2 (Equivalent Dose in 2 Gy fractions) to the clinical target volume of 70.0 Gy. During follow up of median 6.66 years, 39.6% patients developed a second relapse. Risk group classification at primary diagnosis based on histology, grading and FIGO stage and how the pelvic tumor boost was administered were independently associated with PFS and OS. Five-year OS was 68% (95% CI (59–75)) for the whole cohort. Five-year OS was 88% (95% CI (75–94)), 72% (95% CI (55–84)) and 38% (95% CI (15–60)) for the stage I low-, intermediate- and high-risk group, respectively. (4) Conclusions: The majority of central pelvic recurrences in RT-naive EC women can be successfully salvaged with radiotherapy. However, survival in patients with high-risk disease remains poor and warrants a more individualized approach to optimize outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas.
- Author
-
Kleppe, Andreas, Albregtsen, Fritz, Trovik, Jone, Kristensen, Gunnar B., and Danielsen, Håvard E.
- Subjects
CANCER prognosis ,CHROMOSOMES ,CONFIDENCE intervals ,STATISTICAL correlation ,DNA ,FEMALE reproductive organ tumors ,TUMOR markers ,DESCRIPTIVE statistics ,DISEASE risk factors - Abstract
Simple Summary: Chromatin organisation affects gene expression and contributes to carcinogenesis. Automatic quantification of chromatin heterogeneity can be applied to identify patients with increased risk of cancer recurrence and death in several cancer types. We aimed to investigate the prognostic role of diversity of chromatin compartments in relation to chromatin heterogeneity and as a potential supplement to pathological risk classifications in gynaecological carcinomas. To this end, we computed the entropy of both chromatin compartment sizes and optical densities within compartments. In analysis of two cohorts consisting of 1037 patients with gynaecological carcinoma, we observed a moderately strong correlation between the prognostic value of the entropies and chromatin heterogeneity. The entropies provided an objective marker, which, integrated with pathological risk classifications, might possibly contribute to the selection of high-risk stage I ovarian carcinoma patients for adjuvant chemotherapy and to preoperative identification of low-risk endometrial carcinoma patients who are candidates for less extensive surgery. Statistical texture analysis of cancer cell nuclei stained for DNA has recently been used to develop a pan-cancer prognostic marker of chromatin heterogeneity. In this study, we instead analysed chromatin organisation by automatically quantifying the diversity of chromatin compartments in cancer cell nuclei. The aim was to investigate the prognostic value of such an assessment in relation to chromatin heterogeneity and as a potential supplement to pathological risk classifications in gynaecological carcinomas. The diversity was quantified by calculating the entropy of both chromatin compartment sizes and optical densities within compartments. We analysed a median of 281 nuclei (interquartile range (IQR), 273 to 289) from 246 ovarian carcinoma patients and a median of 997 nuclei (IQR, 502 to 1452) from 791 endometrial carcinoma patients. The prognostic value of the entropies and chromatin heterogeneity was moderately strongly correlated (r ranged from 0.68 to 0.73), but the novel marker was observed to provide additional prognostic information. In multivariable analysis with clinical and pathological markers, the hazard ratio associated with the novel marker was 2.1 (95% CI, 1.3 to 3.5) in ovarian carcinoma and 2.4 (95% CI, 1.5 to 3.9) in endometrial carcinoma. Integration with pathological risk classifications gave three risk groups with distinctly different prognoses. This suggests that the novel marker of diversity of chromatin compartments might possibly contribute to the selection of high-risk stage I ovarian carcinoma patients for adjuvant chemotherapy and low-risk endometrial carcinoma patients for less extensive surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer.
- Author
-
Skipar, Kjersti, Hompland, Tord, Lund, Kjersti Vassmo, Løndalen, Ayca, Malinen, Eirik, Kristensen, Gunnar B., Lindemann, Kristina, Nakken, Esten S., Bruheim, Kjersti, and Lyng, Heidi
- Subjects
- *
CERVICAL cancer , *MAGNETIC resonance imaging , *CHEMORADIOTHERAPY , *RECTAL cancer , *OXYGEN consumption , *DIFFUSION coefficients , *HEART failure - Abstract
• In cervical cancer, multiparametric MR images were fused into hypoxia images. • Imaging-based hypoxic fraction (HF) identified low-risk patients with 95% precision. • Integration of MRI (HF) and FDG-PET (SUV) improved detection of high-risk patients. • A candidate multimodal imaging biomarker, HF/SUV 50 , was defined. • HF/SUV 50 is based on standard diagnostic images and feasible in clinical practice. MRI, applying dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) sequences, and 18F-fluorodeoxyglucose (18F-FDG) PET/CT provide information about tumor aggressiveness that is unexploited in treatment of locally advanced cervical cancer (LACC). We investigated the potential of a multimodal combination of imaging parameters for classifying patients according to their risk of recurrence. Eighty-two LACC patients with diagnostic MRI and FDG-PET/CT, treated with chemoradiotherapy, were collected. Thirty-eight patients with MRI only were included for validation of MRI results. Endpoints were survival (disease-free, cancer-specific, overall) and tumor control (local, locoregional, distant). Ktrans, reflecting vascular function, apparent diffusion coefficient (ADC), reflecting cellularity, and standardized uptake value (SUV), reflecting glucose uptake, were extracted from DCE-MR, DW-MR and FDG-PET images, respectively. By applying an oxygen consumption and supply-based method, ADC and Ktrans parametric maps were voxel-wise combined into hypoxia images that were used to determine hypoxic fraction (HF). HF showed a stronger association with outcome than the single modality parameters. This association was confirmed in the validation cohort. Low HF identified low-risk patients with 95% precision. Based on the 50th SUV-percentile (SUV 50), patients with high HF were divided into an intermediate- and high-risk group with high and low SUV 50 , respectively. This defined a multimodality biomarker, HF/SUV 50. HF/SUV 50 increased the precision of detecting high-risk patients from 41% (HF alone) to 57% and showed prognostic significance in multivariable analysis for all endpoints. Multimodal combination of MR- and FDG-PET/CT-images improves classification of LACC patients compared to single modality images and clinical factors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
- Author
-
Vergote, Ignace, Coens, Corneel, Nankivell, Matthew, Kristensen, Gunnar B, Parmar, Mahesh K B, Ehlen, Tom, Jayson, Gordon C, Johnson, Nick, Swart, Ann Marie, Verheijen, René, McCluggage, W Glenn, Perren, Tim, Panici, Pierluigi Benedetti, Kenter, Gemma, Casado, Antonio, Mendiola, Cesar, Stuart, Gavin, Reed, Nick S, Kehoe, Sean, and EORTC
- Subjects
- *
CANCER chemotherapy , *SURGERY , *OVARIAN cancer , *BIOPSY , *HETEROGENEITY , *ANTHROPOMETRY , *CLINICAL trials , *COMBINED modality therapy , *COMPARATIVE studies , *GYNECOLOGIC surgery , *FEMALE reproductive organ tumors , *RESEARCH methodology , *MEDICAL cooperation , *OVARIAN tumors , *RESEARCH , *RESEARCH funding , *TIME , *TUMOR classification , *PERITONEUM tumors , *EVALUATION research , *CYTOREDUCTIVE surgery , *TUMOR treatment - Abstract
Background: Individual patient data from two randomised trials comparing neoadjuvant chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to examine long-term outcomes for patients and to identify any preferable therapeutic approaches for subgroup populations.Methods: We did a per-protocol pooled analysis of individual patient data from the European Organisation for Research and Treatment of Cancer (EORTC) 55971 trial (NCT00003636) and the Medical Research Council Chemotherapy Or Upfront Surgery (CHORUS) trial (ISRCTN74802813). In the EORTC trial, eligible women had biopsy-proven International Federation of Gynecology and Obstetrics (FIGO) stage IIIC or IV invasive epithelial tubo-ovarian carcinoma. In the CHORUS trial, inclusion criteria were similar to those of the EORTC trial, and women with apparent FIGO stage IIIA and IIIB disease were also eligible. The main aim of the pooled analysis was to show non-inferiority in overall survival with neoadjuvant chemotherapy compared with upfront debulking surgery, using the reverse Kaplan-Meier method. Tests for heterogeneity were based on Cochran's Q heterogeneity statistic.Findings: Data for 1220 women were included in the pooled analysis, 670 from the EORTC trial and 550 from the CHORUS trial. 612 women were randomly allocated to receive upfront debulking surgery and 608 to receive neoadjuvant chemotherapy. Median follow-up was 7·6 years (IQR 6·0-9·6; EORTC, 9·2 years [IQR 7·3-10·4]; CHORUS, 5·9 years [IQR 4·3-7·4]). Median age was 63 years (IQR 56-71) and median size of the largest metastatic tumour at diagnosis was 8 cm (IQR 4·8-13·0). 55 (5%) women had FIGO stage II-IIIB disease, 831 (68%) had stage IIIC disease, and 230 (19%) had stage IV disease, with staging data missing for 104 (9%) women. In the entire population, no difference in median overall survival was noted between patients who underwent neoadjuvant chemotherapy and upfront debulking surgery (27·6 months [IQR 14·1-51·3] and 26·9 months [12·7-50·1], respectively; hazard ratio [HR] 0·97, 95% CI 0·86-1·09; p=0·586). Median overall survival for EORTC and CHORUS patients was significantly different at 30·2 months (IQR 15·7-53·7) and 23·6 months (10·5-46·9), respectively (HR 1·20, 95% CI 1·06-1·36; p=0·004), but was not heterogeneous (Cochran's Q, p=0·17). Women with stage IV disease had significantly better outcomes with neoadjuvant chemotherapy compared with upfront debulking surgery (median overall survival 24·3 months [IQR 14·1-47·6] and 21·2 months [10·0-36·4], respectively; HR 0·76, 95% CI 0·58-1·00; p=0·048; median progression-free survival 10·6 months [7·9-15·0] and 9·7 months [5·2-13·2], respectively; HR 0·77, 95% CI 0·59-1·00; p=0·049).Interpretation: Long-term follow-up data substantiate previous results showing that neoadjuvant chemotherapy and upfront debulking surgery result in similar overall survival in advanced tubo-ovarian cancer, with better survival in women with stage IV disease with neoadjuvant chemotherapy. This pooled analysis, with long-term follow-up, shows that neoadjuvant chemotherapy is a valuable treatment option for patients with stage IIIC-IV tubo-ovarian cancer, particularly in patients with a high tumour burden at presentation or poor performance status.Funding: National Cancer Institute and Vlaamse Liga tegen kanker (Flemish League against Cancer). [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. Chromatin organisation and cancer prognosis: a pan-cancer study.
- Author
-
Kleppe, Andreas, Albregtsen, Fritz, Vlatkovic, Ljiljana, Pradhan, Manohar, Nielsen, Birgitte, Hveem, Tarjei S, Askautrud, Hanne A, Kristensen, Gunnar B, Nesbakken, Arild, Trovik, Jone, Wæhre, Håkon, Tomlinson, Ian, Shepherd, Neil A, Novelli, Marco, Kerr, David J, and Danielsen, Håvard E
- Subjects
- *
CHROMATIN , *CANCER prognosis , *GENE expression , *MACHINE learning , *CANCER invasiveness , *CELL nuclei , *CHROMOSOMES , *COLON tumors , *COMPARATIVE studies , *DEGENERATION (Pathology) , *DIAGNOSTIC imaging , *GENES , *INFORMATION science , *RESEARCH methodology , *MEDICAL cooperation , *COMPUTERS in medicine , *MICROSCOPY , *RESEARCH , *RESEARCH funding , *STAINS & staining (Microscopy) , *TUMOR classification , *EVALUATION research , *PREDICTIVE tests , *TUMOR treatment ,RECTUM tumors ,RESEARCH evaluation - Abstract
Background: Chromatin organisation affects gene expression and regional mutation frequencies and contributes to carcinogenesis. Aberrant organisation of DNA has been correlated with cancer prognosis in analyses of the chromatin component of tumour cell nuclei using image texture analysis. As yet, the methodology has not been sufficiently validated to permit its clinical application. We aimed to define and validate a novel prognostic biomarker for the automatic detection of heterogeneous chromatin organisation.Methods: Machine learning algorithms analysed the chromatin organisation in 461 000 images of tumour cell nuclei stained for DNA from 390 patients (discovery cohort) treated for stage I or II colorectal cancer at the Aker University Hospital (Oslo, Norway). The resulting marker of chromatin heterogeneity, termed Nucleotyping, was subsequently independently validated in six patient cohorts: 442 patients with stage I or II colorectal cancer in the Gloucester Colorectal Cancer Study (UK); 391 patients with stage II colorectal cancer in the QUASAR 2 trial; 246 patients with stage I ovarian carcinoma; 354 patients with uterine sarcoma; 307 patients with prostate carcinoma; and 791 patients with endometrial carcinoma. The primary outcome was cancer-specific survival.Findings: In all patient cohorts, patients with chromatin heterogeneous tumours had worse cancer-specific survival than patients with chromatin homogeneous tumours (univariable analysis hazard ratio [HR] 1·7, 95% CI 1·2-2·5, in the discovery cohort; 1·8, 1·0-3·0, in the Gloucester validation cohort; 2·2, 1·1-4·5, in the QUASAR 2 validation cohort; 3·1, 1·9-5·0, in the ovarian carcinoma cohort; 2·5, 1·8-3·4, in the uterine sarcoma cohort; 2·3, 1·2-4·6, in the prostate carcinoma cohort; and 4·3, 2·8-6·8, in the endometrial carcinoma cohort). After adjusting for established prognostic patient characteristics in multivariable analyses, Nucleotyping was prognostic in all cohorts except for the prostate carcinoma cohort (HR 1·7, 95% CI 1·1-2·5, in the discovery cohort; 1·9, 1·1-3·2, in the Gloucester validation cohort; 2·6, 1·2-5·6, in the QUASAR 2 cohort; 1·8, 1·1-3·0, for ovarian carcinoma; 1·6, 1·0-2·4, for uterine sarcoma; 1·43, 0·68-2·99, for prostate carcinoma; and 1·9, 1·1-3·1, for endometrial carcinoma). Chromatin heterogeneity was a significant predictor of cancer-specific survival in microsatellite unstable (HR 2·9, 95% CI 1·0-8·4) and microsatellite stable (1·8, 1·2-2·7) stage II colorectal cancer, but microsatellite instability was not a significant predictor of outcome in chromatin homogeneous (1·3, 0·7-2·4) or chromatin heterogeneous (0·8, 0·3-2·0) stage II colorectal cancer.Interpretation: The consistent prognostic prediction of Nucleotyping in different biological and technical circumstances suggests that the marker of chromatin heterogeneity can be reliably assessed in routine clinical practice and could be used to objectively assist decision making in a range of clinical settings. An immediate application would be to identify high-risk patients with stage II colorectal cancer who might have greater absolute benefit from adjuvant chemotherapy. Clinical trials are warranted to evaluate the survival benefit and cost-effectiveness of using Nucleotyping to guide treatment decisions in multiple clinical settings.Funding: The Research Council of Norway, the South-Eastern Norway Regional Health Authority, the National Institute for Health Research, and the Wellcome Trust. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
24. Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced cervical cancer.
- Author
-
Lund, Kjersti V., Simonsen, Trude G., Hompland, Tord, Kristensen, Gunnar B., and Rofstad, Einar K.
- Subjects
- *
CERVICAL cancer , *MAGNETIC resonance imaging , *BIOMARKERS , *RESONATORS , *CAVITY resonators - Abstract
Background and purpose Several investigators have indicated that dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has the potential to provide biomarkers for personalized treatment of cervical carcinoma. However, some clinical studies have suggested that treatment failure is associated with low tumor signal enhancement, whereas others have reported associations between high signal enhancement and poor outcome. The purpose of this investigation was to clear up these conflicting reports and to provide a method for identifying biomarkers that easily can be implemented in routine DCE-MRI diagnostics. Methods The study involved 85 patients (FIGO stage IB through IVA) treated with concurrent chemoradiotherapy. Low-enhancing tumor volume (LETV) and low-enhancing tumor fraction (LETF), defined as the volume and fractional volume of low-enhancing voxels, respectively, were calculated from signal intensities recorded within 1 min after contrast administration by using two methods reported to give conflicting conclusions. Results Multivariate analysis involving tumor volume, lymph node status, FIGO stage, and LETV or LETF revealed that LETV and LETF provided independent prognostic information on treatment outcome, independent of the method of calculation. Conclusion Low signal enhancement is associated with poor prognosis in cervical carcinoma, and biomarkers predicting poor outcome can be provided by short-term DCE-MRI without advanced image analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
25. MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer.
- Author
-
Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, and Lyng H
- Subjects
- Algorithms, Animals, Cell Line, Tumor, Chemoradiotherapy, Contrast Media, Epithelial-Mesenchymal Transition genetics, Female, G2 Phase Cell Cycle Checkpoints genetics, Gene Expression Profiling methods, HeLa Cells, Humans, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, M Phase Cell Cycle Checkpoints genetics, Mice, Mice, Nude, Neoplasm Transplantation, Nitroimidazoles, Oxidative Phosphorylation, Oxygen Consumption, Prognosis, Treatment Outcome, Uterine Cervical Neoplasms diagnostic imaging, Uterine Cervical Neoplasms genetics, Uterine Cervical Neoplasms therapy, Magnetic Resonance Imaging methods, Tumor Hypoxia genetics, Uterine Cervical Neoplasms metabolism
- Abstract
Tumor hypoxia levels range from mild to severe and have different biological and therapeutical consequences but are not easily assessable in patients. Here we present a method based on diagnostic dynamic contrast enhanced (DCE) MRI that reflects a continuous range of hypoxia levels in patients with tumors of cervical cancer. Hypoxia images were generated using an established approach based on pixel-wise combination of DCE-MRI parameters ν
e and Ktrans , representing oxygen consumption and supply, respectively. Using two tumor models, an algorithm to retrieve surrogate measures of hypoxia levels from the images was developed and validated by comparing the MRI-defined levels with hypoxia levels reflected in pimonidazole-stained histologic sections. An additional indicator of hypoxia levels in patient tumors was established on the basis of expression of nine hypoxia-responsive genes; a strong correlation was found between these indicator values and MRI-defined hypoxia levels in 63 patients. Chemoradiotherapy outcome of 74 patients was most strongly predicted by moderate hypoxia levels, whereas more severe or milder levels were less predictive. By combining gene expression profiles and MRI-defined hypoxia levels in cancer hallmark analysis, we identified a distribution of levels associated with each hallmark; oxidative phosphorylation and G2 -M checkpoint were associated with moderate hypoxia, epithelial-to-mesenchymal transition, and inflammatory responses with significantly more severe levels. At the mildest levels, IFN response hallmarks together with HIF1A protein expression by IHC appeared significant. Thus, our method visualizes the distribution of hypoxia levels within patient tumors and has potential to distinguish levels of different prognostic and biological significance. SIGNIFICANCE: These findings present an approach to image a continuous range of hypoxia levels in tumors and demonstrate the combination of imaging with molecular data to better understand the biology behind these different levels., (©2020 American Association for Cancer Research.)- Published
- 2020
- Full Text
- View/download PDF
26. Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity.
- Author
-
Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, and Lyng H
- Subjects
- Adult, Aged, Aged, 80 and over, Chemoradiotherapy adverse effects, Diagnostic Imaging, Female, Gene Expression Profiling, Humans, Middle Aged, Norway epidemiology, Prognosis, Progression-Free Survival, Treatment Outcome, Tumor Hypoxia drug effects, Tumor Hypoxia radiation effects, Uterine Cervical Neoplasms diagnostic imaging, Uterine Cervical Neoplasms genetics, Biomarkers, Tumor genetics, Neoplasm Proteins genetics, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms radiotherapy
- Abstract
Background: Emerging biomarkers from medical imaging or molecular characterization of tumour biopsies open up for combining the two and exploiting their synergy in treatment planning of cancer patients. We generated a paired data set of imaging- and gene-based hypoxia biomarkers in cervical cancer, appraised the influence of intratumour heterogeneity in patient classification, and investigated the benefit of combining the methodologies in prediction of chemoradiotherapy failure., Methods: Hypoxic fraction from dynamic contrast enhanced (DCE)-MR images and an expression signature of six hypoxia-responsive genes were assessed as imaging- and gene-based biomarker, respectively in 118 patients., Findings: Dichotomous biomarker cutoff to yield similar hypoxia status by imaging and genes was defined in 41 patients, and the association was validated in the remaining 77 patients. The two biomarkers classified 75% of 118 patients with the same hypoxia status, and inconsistent classification was not related to imaging-defined intratumour heterogeneity in hypoxia. Gene-based hypoxia was independent on tumour cell fraction in the biopsies and showed minor heterogeneity across multiple samples in 9 tumours. Combining imaging- and gene-based classification gave a significantly better prediction of PFS than one biomarker alone. A combined dichotomous biomarker optimized in 77 patients showed a large separation in PFS between more and less hypoxic tumours, and separated the remaining 41 patients with different PFS. The combined biomarker showed prognostic value together with tumour stage in multivariate analysis., Interpretation: Combining imaging- and gene-based biomarkers may enable more precise and informative assessment of hypoxia-related chemoradiotherapy resistance in cervical cancer., Funding: Norwegian Cancer Society, South-Eastern Norway Regional Health Authority, and Norwegian Research Council., Competing Interests: Declaration of Competing Interest HL is registered as inventor of a patent application covering the clinical use of the hypoxia gene signature (WO2013/124,738)., (Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
27. Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes.
- Author
-
Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, and Carlson JW
- Subjects
- Chromosome Aberrations, Computational Biology methods, DNA Copy Number Variations, Female, Gene Expression Profiling, Gene Ontology, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Kaplan-Meier Estimate, Molecular Diagnostic Techniques, Neoplasm Grading, Prognosis, Proportional Hazards Models, Proteomics methods, Sarcoma mortality, Uterine Neoplasms mortality, Biomarkers, Tumor, Sarcoma diagnosis, Sarcoma etiology, Uterine Neoplasms diagnosis, Uterine Neoplasms etiology
- Abstract
Purpose: Undifferentiated uterine sarcomas (UUS) are rare, extremely deadly, sarcomas with no effective treatment. The goal of this study was to identify novel intrinsic molecular UUS subtypes using integrated clinical, histopathologic, and molecular evaluation of a large, fully annotated, patient cohort., Experimental Design: Fifty cases of UUS with full clinicopathologic annotation were analyzed for gene expression ( n = 50), copy-number variation (CNV, n = 40), cell morphometry ( n = 39), and protein expression ( n = 22). Gene ontology and network enrichment analysis were used to relate over- and underexpressed genes to pathways and further to clinicopathologic and phenotypic findings., Results: Gene expression identified four distinct groups of tumors, which varied in their clinicopathologic parameters. Gene ontology analysis revealed differential activation of pathways related to genital tract development, extracellular matrix (ECM), muscle function, and proliferation. A multivariable, adjusted Cox proportional hazard model demonstrated that RNA group, mitotic index, and hormone receptor expression influence patient overall survival (OS). CNV arrays revealed characteristic chromosomal changes for each group. Morphometry demonstrated that the ECM group, the most aggressive, exhibited a decreased cell density and increased nuclear area. A cell density cutoff of 4,300 tumor cells per mm
2 could separate ECM tumors from the remaining cases with a sensitivity of 83% and a specificity of 94%. IHC staining of MMP-14, Collagens 1 and 6, and Fibronectin proteins revealed differential expression of these ECM-related proteins, identifying potential new biomarkers for this aggressive sarcoma subgroup., Conclusions: Molecular evaluation of UUS provides novel insights into the biology, prognosis, phenotype, and possible treatment of these tumors., (©2019 American Association for Cancer Research.)- Published
- 2019
- Full Text
- View/download PDF
28. [Properties of cancer cell DNA affects the prognosis].
- Author
-
Kildal W, Pradhan M, Cyll K, Jacobsen JE, Kristensen GB, and Danielsen HE
- Subjects
- Colorectal Neoplasms genetics, Endometrial Neoplasms genetics, Female, Genomic Instability, Humans, Male, Ovarian Neoplasms genetics, Prognosis, Prostatic Neoplasms genetics, Carcinoma genetics, DNA, Neoplasm genetics, Neoplasms genetics, Ploidies
- Abstract
Background: When diagnosing cancer, it is often difficult to predict the further growth and spread of the tumour. One of the features of cancer is an abnormality in the amount of DNA in cancer cell nuclei, so-called DNA aneuploidy. Extensive abnormalities are often due to an unstable genome, which leads to an accumulation of mutations, dysregulation of genes and loss of cell cycle control. This article aims to provide an overview of the prognostic value of DNA ploidy analyses in ovarian, endometrial, prostate and colorectal carcinoma., Material and Method: This review article is based on literature searches in PubMed for the period 2000–2016., Results: The search resulted in 308 articles. Thirty-three of these, representing an analysis of more than 18 000 tumours, fulfilled the inclusion criteria. In 30 of the 33 articles, a significant correlation was found between DNA ploidy and disease outcome for patients with ovarian, endometrial, prostate and colorectal carcinoma. Patients with aneuploid tumours had a poorer prognosis than those with diploid tumours., Interpretation: DNA ploidy analysis is a prognostic method for patients with ovarian and endometrial carcinoma, and is used as a guide to options for supplemental treatment and fertility-sparing surgery. A review of publications in recent years of DNA ploidy analyses for prostate and colorectal carcinoma reveals that these patient groups may also benefit from these measurements. In general terms, DNA ploidy analyses may help to increase knowledge of who needs supplemental treatment and who does not – which may be advantageous in avoiding overtreatment.
- Published
- 2017
- Full Text
- View/download PDF
29. Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer.
- Author
-
Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, and Lyng H
- Subjects
- Adult, Aged, Aged, 80 and over, Chemoradiotherapy, Cohort Studies, Combined Modality Therapy, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Hypoxia metabolism, Image Enhancement, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Proportional Hazards Models, Treatment Failure, Treatment Outcome, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms therapy, Young Adult, Hypoxia genetics, Magnetic Resonance Imaging methods, Transcriptome, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms genetics
- Abstract
Purpose: A 31-gene expression signature reflected in dynamic contrast enhanced (DCE)-MR images and correlated with hypoxia-related aggressiveness in cervical cancer was identified in previous work. We here aimed to construct a dichotomous classifier with key signature genes and a predefined classification threshold that separated cervical cancer patients into a more and less hypoxic group with different outcome to chemoradiotherapy., Experimental Design: A training cohort of 42 patients and two independent cohorts of 108 and 131 patients were included. Gene expression data were generated from tumor biopsies by two Illumina array generations (WG-6, HT-12). Technical transfer of the classifier to a reverse transcription quantitative PCR (RT-qPCR) platform was performed for 74 patients. The amplitude ABrix in the Brix pharmacokinetic model was extracted from DCE-MR images of 64 patients and used as an indicator of hypoxia., Results: Classifier candidates were constructed by integrative analysis of ABrix and gene expression profiles in the training cohort and evaluated by a leave-one-out cross-validation approach. On the basis of their ability to separate patients correctly according to hypoxia status, a 6-gene classifier was identified. The classifier separated the patients into two groups with different progression-free survival probability. The robustness of the classifier was demonstrated by successful validation of hypoxia association and prognostic value across cohorts, array generations, and assay platforms. The prognostic value was independent of existing clinical markers, regardless of clinical endpoints., Conclusions: A robust DCE-MRI-associated gene classifier has been constructed that may be used to achieve an early indication of patients' risk of hypoxia-related chemoradiotherapy failure. Clin Cancer Res; 22(16); 4067-76. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.